Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia [Phase 4]
A Phase 4 clinical trial update reports sustained treatment-free remission in patients with BCR-ABL+ chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase [Phase 2]
Phase 2 trial investigating nilotinib as first-line therapy for chronic myeloid leukemia in early chronic phase has been completed.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial update evaluating nilotinib and imatinib mesylate in early chronic phase chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate [NA]
Clinical trial update of imatinib mesylate for various myeloproliferative and related neoplasms including CMML, CML, polycythemia vera, hype…
-
CLINICAL_TRIALS trial_result · 2021-12-30Clinical Trial Update: Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors [Phase 4]
Phase 4 safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients previously treated with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia [Phase 3]
Phase 3 trial comparing ponatinib vs nilotinib in chronic phase chronic myeloid leukemia has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: European Stop Tyrosine Kinase Inhibitor Study [Phase 3]
A Phase 3 clinical trial update for a study on tyrosine kinase inhibitors in chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response [Phase 2]
Phase 2 trial investigating imatinib mesylate with zoledronic acid in chronic myeloid leukemia patients in cytogenetic response without mole…
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 [NA]
A completed bosutinib treatment extension study for CML patients who previously participated in related bosutinib trials; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha [Phase 2]
Phase 2 extension study evaluating efficacy and safety of STI571 in chronic myeloid leukemia patients refractory to or intolerant of interfe…
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase [Phase 2]
Phase 2 trial evaluating LBH589B in adult patients with refractory chronic myeloid leukemia in accelerated or blast phase; study terminated …
-
CLINICAL_TRIALS trial_result · 2021-07-01Clinical Trial Update: An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment [Phase 4]
Phase 4 exploratory trial evaluating adverse event improvement when chronic myeloid leukemia patients switch from imatinib to nilotinib.
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/2 study of oral AMN107 (imatinib) in adults with chronic myeloid leukemia and other hematologic malignancies has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis [Phase 2]
Phase 2 extension study evaluating safety and anti-leukemic effects of imatinib mesylate in Philadelphia chromosome-positive chronic myeloid…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses [Phase 2]
Phase 2 dose-ranging trial of ponatinib in patients with resistant chronic phase chronic myeloid leukemia to characterize efficacy and safet…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies [NA]
A completed clinical trial evaluating intensity modulated total marrow irradiation (IM-TMI) for advanced hematologic malignancies, with resu…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) [Phase 4]
Phase 4 trial update evaluating dasatinib as first-line therapy for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) complete…
-
CLINICAL_TRIALS trial_result · 2021-05-20Clinical Trial Update: Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations [Phase 4]
A Phase 4 clinical trial investigating nilotinib in Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase patients with…
-
CLINICAL_TRIALS trial_result · 2021-05-12Clinical Trial Update: Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment [Phase 2]
Phase 2 clinical trial evaluating the value of adding pioglitazone to treatment in chronic myeloid leukemia with BCR-ABL positivity.
-
CLINICAL_TRIALS trial_result · 2021-04-15Clinical Trial Update: Allogeneic Stem Cell Transplantation for Children With CML [Phase 2, Phase 3]
Phase 2/3 trial updating outcomes of allogeneic stem cell transplantation in children with chronic myeloid leukemia; study completed.
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints [Phase 2]
Phase 2 exploratory trial evaluating high-dose Glivec (imatinib) in chronic myeloid leukemia in chronic phase using molecular endpoints; stu…
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 clinical trial updating cardiovascular assessment of ponatinib as a third-line treatment in chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients [Phase 2]
Phase 2 study evaluating nilotinib treatment-free remission in chronic myeloid leukemia patients has completed, with results posted January …
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) [Phase 2]
The ENESTop Phase 2 trial reports treatment-free remission after achieving sustained deep molecular response (MR4.5) in chronic myeloid leuk…
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells [Phase 2]
Phase 2 trial evaluating nilotinib 300 mg twice daily in newly diagnosed chronic-phase CML to verify disappearance of CD34+/Lin-Ph+ cells.